| Autor: |
Mariana Sandoval Lourenço, Patricia Momoyo Y. Zitelli, Marlone Cunha-Silva, Arthur Ivan N. Oliveira, Roque Gabriel Rezende de Lima, Evandro de Oliveira Souza, Claudia P. Oliveira, Tiago Sevá-Pereira, Flair J. Carrilho, Mario G. Pessoa, Daniel F. Mazo |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Clinics, Vol 76 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1980-5322 |
| DOI: |
10.6061/clinics/2021/e3186 |
| Popis: |
OBJECTIVES: Despite higher rates of sustained virologic response (SVR), important concerns remain when patients with decompensated cirrhosis due to hepatitis C virus (HCV) are treated with direct-acting antiviral agents (DAA). Questions include efficacy, safety, and the magnitude of liver function improvement. Here, we aimed to evaluate HCV treatment data in this specific population in Brazil. METHODS: We included 85 patients with decompensated cirrhosis submitted to HCV therapy with DAA followed at two academic tertiary centers in the southeastern region of Brazil. RESULTS: Seventy-nine patients (92.9%) were Child-Pugh (CP) score B, and six (7.1%) were CP score C. The mean MELD score was 12.86. The most common treatment was sofosbuvir plus daclatasvir±ribavirin for 24 weeks. The overall intention-to-treat (ITT) SVR rate was 87.4% (74/85) and modified-ITT 96.1% (74/77). ITT SVR was associated with lower baseline INR values (p=0.029). Adverse events (AE) occurred in 57.9% (44/76) of patients. Serious AE were reported in 12.8% (10/78), and were related to the presence of hepatic encephalopathy (p=0.027). SVR was associated with improvement in CP (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
